drugset / Trial / NCT00279214

Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock

NCT00279214

Phase 4 Completed 43 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving drotrecogin alfa (activated).

Timeline

Start
2005-11
Primary completion
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Drotrecogin alfa (activated) Protein / enzyme biologic Other